Risk factors
Travere Therapeutics (TVTX) risk factors
Item 1A of every Travere Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors62 risks9 new6 dropped19 reworded
Pricing pressure is more prominent, including Medicaid rebates, prior authorization, managed-care restrictions, and possible MFN changes.
Filed Feb 19, 2026 - FY2024 10-K risk factors59 risks
Commercial success depends entirely on sales adoption of FILSPARI for primary IgAN and Thiola.
Filed Feb 21, 2025